The invention relates to compounds of the general formula (I):
##STR00001## wherein Ar is optionally substituted aryl or heteroaryl;
A is (i) --O--, --S--, --SO.sub.2--, --NH--, (ii) a C.sub.1-4-alkyl- or
C.sub.1-6-acyl-substituted nitrogen atom or (iii) a C.sub.1-8-alkylene
chain or a heteroalkylene chain having 2 to 8 chain atoms, which
optionally contains at least one unsaturation, and which may be
substituted and/or contain a bridge to form a saturated or partially or
fully unsaturated ring having 3-8 ring members; B is
--C(R.sub.4)(R.sub.5)--, --OC(R.sub.4)(R.sub.5)--,
--N(R.sub.6)C(R.sub.4)(R.sub.5)--, --N(R.sub.6)--, --O--, --S-- or
--SO.sub.2--; R is optionally substituted C.sub.3-8-cycloalkyl, aryl or
heteroaryl; R.sub.1 is (i) a saturated or unsaturated azacyclic or
aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring,
which has 4 to 7 ring members, or a saturated aminoazabicyclic,
azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which
rings optionally are substituted in one or more positions, or a group
--[C(R.sub.4)(R.sub.5)].sub.xN(R.sub.2a)(R.sub.3a)]; R.sub.2a, R.sub.3a,
R.sub.4, R.sub.5, R.sub.6 and x are as defined in the claims, and n is 0
or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms
thereof. The compounds may be prepared by per se conventional methods
and can be used for treating a human or animal subject suffering from a
serotonin-related disorder, such as eating disorders, especially obesity,
memory disorders, schizophrenia, mood disorders, anxiety disorders, pain,
sexual dysfunctions, and urinary disorders The invention also relates to
such use as well as to pharmaceutical compositions comprising a compound
of formula (I).